Published in Clin Gastroenterol Hepatol on August 20, 2010
HIV-HCV Coinfection: Impact of Immune Dysfunction | NCT00575315
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One (2014) 1.01
Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol (2014) 0.98
Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci (2011) 0.92
Effect of HIV on liver fibrosis among HCV-infected African Americans. Clin Infect Dis (2013) 0.80
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci (2016) 0.80
Hepatitis C Virus and HIV Type 1 Co-Infection. Infect Dis Rep (2013) 0.79
Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore) (2016) 0.75
Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection. J Acquir Immune Defic Syndr (2016) 0.75
Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection. J Clin Transl Hepatol (2016) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis (2006) 2.08
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07
Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA (2001) 1.95
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology (2009) 1.64
Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut (2003) 1.48
Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol (2005) 1.19
Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med (2006) 1.09
Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat (2007) 1.01
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis (2008) 0.90
Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother (2005) 0.89
Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat (2005) 0.87
There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV. Braz J Med Biol Res (2007) 0.85
Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol (2004) 0.85
Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection. J Infect (2006) 0.80
Pathological evolution of hepatitis C virus-"Healthy carriers". World J Gastroenterol (2008) 0.80
Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol (2007) 0.79
Role of liver biopsy in the evaluation of hepatitis C virus infection in HIV coinfection. Clin Infect Dis (2005) 0.79
The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr (2003) 0.78
The HIV-coinfected patient: managing viral hepatitis. J Acquir Immune Defic Syndr (2007) 0.78
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet (2005) 2.35
Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology (2012) 2.31
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Steroid use in acute liver failure. Hepatology (2013) 2.23
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr (2007) 1.99
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90